-
describe the current treatment landscape of rheumatoid arthritis (RA).
-
explain the mechanism of action of interleukin-6 receptor (IL-6R) inhibitors and their biosimilars.
-
explain the role of IL-6R inhibitors and their biosimilars in the management of RA.
-
identify the right patients for IL-6R therapy.
-
compare the efficacy and safety of IL-6R inhibitors and tumor necrosis factor inhibitors.
About This Course
This course has been designed to provide doctors and other relevant healthcare professionals with a practical overview of the management of rheumatoid arthritis with interleukin-6 receptor inhibition therapy, with a specific focus on tocilizumab and its biosimilars. This course should take approximately 60 minutes to complete.
This course has a 2-year expiry date of 29th July, 2026. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.
CME/CPD Information
This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®). This accreditation certifies the quality and relevance of the educational content.
Learning Outcomes
By the end of this course, you should be able to:
Expert Faculty
This course has been made in close collaboration with:
Course curriculum
-
-
Welcome to the Course
-
-
-
Introduction to Precourse Quiz
-
Precourse Quiz
-
-
-
Overview of Rheumatoid Arthritis
-
-
-
The Treatment Landscape of Rheumatoid Arthritis
-
-
-
Interleukin-6 Receptor Inhibitors and Their Biosimilars
-
-
-
Selecting the Right Patients for Interleukin-6 Receptor Inhibitors
-
-
-
Comparing Interleukin-6 Receptor Inhibitors and TNF Inhibitors
-
-
-
Introduction to Final Quiz
-
Final Quiz
-
-
-
Conclusions and Take-Home Messages
-
Course Feedback Survey
-
Funding
-
About this course
- Free
- 13 lessons
- 0 hours of video content